Pharmaceutical company Boehringer Ingelheim expands and invests $57 million in Athens



Boehringer Ingelheim, a research-driven global pharmaceutical development and manufacturing company based in Germany, will expand its global animal health innovation center in Athens, Georgia. The $57 million investment will increase lab space and bring additional research and development capabilities and activities, including 55 new positions, to the site.

“Boehringer Ingelheim has been a fantastic member of our Georgia Life Sciences community, and we are thrilled to see them continue to choose Georgia for growth,” Governor Kemp said. “Georgia’s university system provides the talent sought by life sciences companies, and our business-friendly environment, combined with our commitment to innovation, continues to create opportunities for hard-working Georgians across the state. . »

As a leading research-driven pharmaceutical company, Boehringer Ingelheim focuses on three business areas: human pharmacy, animal health and biopharmaceutical contract manufacturing. The company manufactures widely respected and widely used vaccines, pest control products and therapeutics for companion animals, horses and livestock.

“Our new, expanded space has been specifically designed to foster closer bonds between teams and colleagues. After working remotely or virtually for so many months, we all appreciate the power of formal, spontaneous collaboration much more,” explained Caroline Belmont, Head of Global Innovation in the US. “The significant investment in expanding and improving our Athens Global Innovation site will not only provide a comfortable and flexible physical space that inspires collaboration, but will also bring many new tools and technologies to spark the innovation that will ultimately help improve animal and human welfare.”

Construction recently began on a new 63,000 square foot facility, located at 1730 Olympic Drive in Athens, which will connect two existing buildings currently housing laboratory and administrative space, as well as a 5,000 square foot extension and renovation partial of Global Innovation facilities in Athens. The new facility is expected to be completed in the spring of 2024. When complete, the expansion will bring Boehringer Ingelheim’s global innovation footprint in Athens to nearly 115,000 square feet and accommodate 55 additional research and development positions on site. Visit the company US Careers Page to learn more about research and development opportunities for Boehringer Ingelheim’s Animal Health business and its Athens, Georgia site.

Sustainability was considered throughout the design process and many sustainable features will be included in the new Global Innovation facility. The new building and expansion will include extensive use of natural light in offices, labs and collaboration spaces, with floor-to-ceiling windows in many areas. Construction debris will be segregated for easy recycling or disposal, as appropriate.

“Boehringer Ingelheim’s expansion into Athens-Clarke County demonstrates their continued commitment to innovation, engagement and developing talent in our community, which reflects the company’s global leadership in healthcare. animal and human,” Mayor Kelly Girtz said. “Boehringer Ingelheim recognizes the strength of Athens-Clarke County as a bioscience and research hub with a vibrant quality of life, and we look forward to our continued collaboration.

Since 2018, Boehringer Ingelheim has invested more than $100 million in its Georgia facilities and increased its employment in the state by more than 200, including its Athens vaccine manufacturing and research site, its US headquarters in Duluth and its poultry vaccine. manufacturing site in Gainesville. The company employs more than 1,200 people in Georgia between locations. Boehringer Ingelheim’s Animal Health business has deep roots in the USA From its beginnings in St. Joseph, Missouri more than 100 years ago, it has grown to encompass seven locations, including three in Georgia.

Director of Life Sciences EJane Caraway represented the Georgia Department of Economic Development (GDEcD) Global Commerce Team on this competitive project in partnership with the Athens-Clarke County Department of Economic Development and Georgia Power.

“With successful growth and the addition of companies like Boehringer Ingelheim, Georgia continues to establish itself as a thriving center for research and innovation within the life sciences industry,” said GDEcD Commissioner Pat Wilson. “Boehringer Ingelheim has long been an important part of our life science community in Georgia, leveraging innovative connections and resources throughout the Georgia University system to conduct cutting-edge research in animal disease prevention and treatment. . It’s always exciting to celebrate growth within an important existing industry, but even more rewarding when the work done in Georgia could potentially have such a significant impact.

There are more than 2,200 clinical trials recruiting or underway in Georgia. From 2014 to 2017, 547 patents were granted to Georgian applicants for medicines and pharmaceuticals. In 2021, Georgia exported $3.2 billion in immunological products and $1.9 billion in medical devices and pharmaceuticals.


About Boehringer Ingelheim
Boehringer Ingelheim Animal Health is working on breakthrough innovation for the prediction, prevention and treatment of disease in animals. For veterinarians, pet owners, producers and governments in more than 150 countries, the company offers a broad, innovative portfolio of products and services to improve the health and well-being of companion animals and the livestock. Learn more about Boehringer Ingelheim Animal Health USA at bi-animalhealth.com.


AllOnGeorgia